Singapore markets closed

EyePoint Pharmaceuticals, Inc. (EYPT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
8.26-0.26 (-3.05%)
At close: 04:00PM EDT
8.65 +0.39 (+4.72%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.52
Open8.50
Bid8.23 x 100
Ask8.29 x 200
Day's range8.19 - 8.69
52-week range5.67 - 30.99
Volume736,628
Avg. volume1,129,482
Market cap430.217M
Beta (5Y monthly)1.60
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

    WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R&D Day on Wednesday, June 26, 2024 from 8:00 a.m. to 9:30 a.m. ET. The R&D Day will feature presentations and a roundtable discussion from key opinion leader (KOL) guest speakers Carl D. Regillo, M.D., F

  • GlobeNewswire

    EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an

  • GlobeNewswire

    EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

    WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 3:20 p.m. ET. A live webcast and subsequent archived